INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tricida, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tricida, Inc. (“Tricida” or “the Company”) (NASDAQ: TCDA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Tricida disclosed in a press release issued on July 15, 2020, that the FDA had notified the Company regarding its New Drug Application (“NDA”) for drug candidate veverimer (TRC101). The FDA notification stated that the agency “ha[d] identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” Based on this news, shares of Tricida fell by 40% the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [e-mail].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.